Per our directory, First Avenue leads pre-seed and seed rounds and may participate through Series A. The firm runs a Life Science Fund I tied to UAB/Birmingham life sciences plus an Opportunity Fund aimed at seed and pre-seed companies.

Public materials for the Opportunity Fund cite checks of roughly $100k–$500k. Life Science Fund I sizing is not published as a single fixed amount; founders should confirm current terms with the firm rather than assuming one check for every deal.

First Avenue is based in Birmingham, AL. Life Science Fund I emphasizes UAB and Birmingham life-sciences deal flow; Opportunity Fund activity can include broader early-stage companies—founders should ask the firm about geography fit for a specific thesis.

Our directory tags biotech/life sciences, healthtech, and enterprise SaaS. The Life Science Fund I is oriented to Birmingham/UAB life sciences; the Opportunity Fund covers seed and pre-seed opportunities across the firm's broader early-stage mandate.

Our directory marks First Avenue as a pre-seed and seed lead. At Series A it more often participates alongside other institutional investors rather than always writing the lead check.

As of April 2024, public reporting noted Opportunity Fund commitments exceeding $2M. We do not list a firm-wide AUM figure because a single verified total across all vehicles is not available in our sources.

Start at firstavenueventures.com and clarify whether Life Science Fund I or the Opportunity Fund is the better fit. Warm intros from Birmingham operators, UAB-affiliated founders, or local angels help; be ready with stage, sector, and capital needs that match the $100k–$500k Opportunity Fund range when relevant.

We do not yet have a dedicated First Avenue Ventures article. For Birmingham early-stage context, see our city and industry hubs covering healthtech and biotech/life sciences, and watch for future Alabama investor coverage.